Akero Therapeutics

NASH on the Cusp: An Emerging Market Opportunity
NASH on the Cusp: An Emerging Market Opportunity
BioSpace
NASH
Viking Therapeutics
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Akero Therapeutics
Hepion Pharmaceuticals
Novo Nordisk
Galmed Pharmaceuticals
Flag link:
Akero's stock sinks as midphase cirrhosis fail sparks flash NASH crash
Akero's stock sinks as midphase cirrhosis fail sparks flash NASH crash
Fierce Biotech
Akero Therapeutics
NASH
efruxifermin
clinical trials
Flag link:
Spotlight – Nash in 2023 and beyond
Spotlight – Nash in 2023 and beyond
EP Vantage
NASH
Boehringer Ingelheim
Zealand Pharma
Akero Therapeutics
Axcella Health
Eli Lilly
Pfizer
Ionis Pharmaceuticals
Cascade
AstraZeneca
Gilead Sciences
Novo Nordisk
Ascletis Pharma
MediciNova
Flag link:
Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio
Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio
Fierce Biotech
Boston Pharmaceuticals
NASH
Novartis
Akero Therapeutics
89Bio
BOS-580
Flag link:
Akero’s NASH drug combined with Ozempic cut liver fat in small study
Akero’s NASH drug combined with Ozempic cut liver fat in small study
Stat
Akero Therapeutics
efruxifermin
NASH
Ozempic
Flag link:
89Bio Enlivened by Nash success
89Bio Enlivened by Nash success
EP Vantage
89Bio
NASH
Akero Therapeutics
pegozafermin
INTERCEPT
Madrigal Pharmaceuticals
Flag link:
89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround
89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround
Endpoints
89Bio
NASH
clinical trials
gozafermin
Akero Therapeutics
Flag link:
Pfizer Makes Supportive Investment in Akero's NASH Drug
Pfizer Makes Supportive Investment in Akero's NASH Drug
BioSpace
Akero Therapeutics
Pfizer
NASH
Flag link:
Analysts hail Akero's midphase NASH data as best in class
Analysts hail Akero's midphase NASH data as best in class
Fierce Biotech
Akero Therapeutics
clinical trials
NASH
efruxifermin
Flag link:
Akero’s success gives a new Nash mechanism hope
Akero’s success gives a new Nash mechanism hope
EP Vantage
Akero Therapeutics
NASH
AKR-001
Flag link:
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
EP Vantage
Bayer
Merck
vericiguat
heart failure
AKR-001
Akero Therapeutics
clinical trials
NASH
Flag link:
Back to business for biotech flotations
Back to business for biotech flotations
EP Vantage
IPOs
BridgeBio
Turning Point Therapeutics
Stoke Therapeutics
Prevail Therapeutics
Atreca
NGM Biopharmaceuticals
Akero Therapeutics
Milestone Pharmaceuticals
Morphic Therapeutics
Karuna
Flag link:
Four More Through the IPO Door as Life Science Firms Raise $465M
Four More Through the IPO Door as Life Science Firms Raise $465M
Xconomy
IPOs
Personalis
Akero Therapeutics
Prevail Therapeutics
Atreca
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
Flag link:
New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero
New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero
BioCentury
IPOs
BridgeBio
Dermavant
Prevail Therapeutics
Atreca
Akero Therapeutics
Flag link:
Upstart Akero continues its swoosh into NASH space with $70M windfall round
Upstart Akero continues its swoosh into NASH space with $70M windfall round
Endpoints
Akero Therapeutics
NASH
AKR-001
Flag link: